The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Pseudorabies Virus Vaccine Market Research Report 2025
Synopsis
Porcine pseudorabies is an acute infectious disease of pigs caused by Pseudorabies virus (PrV). The disease is fulminant in pigs. It can cause abortion of pregnant sows, stillbirth, infertility of boars, death of a large number of newborn piglets, difficulty in breathing of fattening pigs, and stagnant growth. It is one of the major infectious diseases that harm the global pig industry.
The global Pseudorabies Virus Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pseudorabies Virus Vaccine include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pseudorabies Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pseudorabies Virus Vaccine.
Report Scope
The Pseudorabies Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pseudorabies Virus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pseudorabies Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Merial Limited
Boehringer Ingelheim Animal Health (USA) Co., Ltd.
Zoetis
Hipra
Anhui Divinity Biological Products
Wuhan Keqian Biological Co., Ltd.
China Biotechnology Co., Ltd.
CHINA ANIMAL HUSBANDRY INDUSTRY
Sichuan Huashen
Haley
Tianbang
Dabei Nong
Harvey
Preh Bio
Jiangsu Nannong High-Tech Co.
Guangxi Liyuan Biological Co., Ltd.
Jilin Zhengye Bioengineering Group
Jilin Heyuan Biological Engineering Co., Ltd.
Huapai Biological Engineering Group Co., Ltd.
Beijing Xinde Weite Technology Co., Ltd.
Beijing Veterinary Biopharmaceutical Factory
Qilu Animal Health Products Co., Ltd.
Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
Yunnan Biopharmaceutical Co.
Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
Liaoning Yikang Biological Co., Ltd.
Shanghui Huahong Biological Engineering Co., Ltd.
Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Segment by Type
Inactivated Vaccine
Naturally Deficient Attenuated Vaccine
Genetic Engineering Vaccine
Segment by Application
Government Tender
Market Sales
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pseudorabies Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pseudorabies Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Porcine pseudorabies is an acute infectious disease of pigs caused by Pseudorabies virus (PrV). The disease is fulminant in pigs. It can cause abortion of pregnant sows, stillbirth, infertility of boars, death of a large number of newborn piglets, difficulty in breathing of fattening pigs, and stagnant growth. It is one of the major infectious diseases that harm the global pig industry.
The global Pseudorabies Virus Vaccine market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of % during the forecast period 2024-2030.
North American market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Pseudorabies Virus Vaccine is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global manufacturers of Pseudorabies Virus Vaccine include Merck, Merial Limited, Boehringer Ingelheim Animal Health (USA) Co., Ltd., Zoetis, Hipra, Anhui Divinity Biological Products, Wuhan Keqian Biological Co., Ltd., China Biotechnology Co., Ltd. and CHINA ANIMAL HUSBANDRY INDUSTRY, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Pseudorabies Virus Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Pseudorabies Virus Vaccine.
Report Scope
The Pseudorabies Virus Vaccine market size, estimations, and forecasts are provided in terms of sales volume (M Doses) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Pseudorabies Virus Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Pseudorabies Virus Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Merck
Merial Limited
Boehringer Ingelheim Animal Health (USA) Co., Ltd.
Zoetis
Hipra
Anhui Divinity Biological Products
Wuhan Keqian Biological Co., Ltd.
China Biotechnology Co., Ltd.
CHINA ANIMAL HUSBANDRY INDUSTRY
Sichuan Huashen
Haley
Tianbang
Dabei Nong
Harvey
Preh Bio
Jiangsu Nannong High-Tech Co.
Guangxi Liyuan Biological Co., Ltd.
Jilin Zhengye Bioengineering Group
Jilin Heyuan Biological Engineering Co., Ltd.
Huapai Biological Engineering Group Co., Ltd.
Beijing Xinde Weite Technology Co., Ltd.
Beijing Veterinary Biopharmaceutical Factory
Qilu Animal Health Products Co., Ltd.
Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
Yunnan Biopharmaceutical Co.
Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
Liaoning Yikang Biological Co., Ltd.
Shanghui Huahong Biological Engineering Co., Ltd.
Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
Segment by Type
Inactivated Vaccine
Naturally Deficient Attenuated Vaccine
Genetic Engineering Vaccine
Segment by Application
Government Tender
Market Sales
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Pseudorabies Virus Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Pseudorabies Virus Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Pseudorabies Virus Vaccine Market Overview
1.1 Product Overview and Scope of Pseudorabies Virus Vaccine
1.2 Pseudorabies Virus Vaccine Segment by Type
1.2.1 Global Pseudorabies Virus Vaccine Market Value Comparison by Type (2024-2030)
1.2.2 Inactivated Vaccine
1.2.3 Naturally Deficient Attenuated Vaccine
1.2.4 Genetic Engineering Vaccine
1.3 Pseudorabies Virus Vaccine Segment by Application
1.3.1 Global Pseudorabies Virus Vaccine Market Value by Application: (2024-2030)
1.3.2 Government Tender
1.3.3 Market Sales
1.4 Global Pseudorabies Virus Vaccine Market Size Estimates and Forecasts
1.4.1 Global Pseudorabies Virus Vaccine Revenue 2019-2030
1.4.2 Global Pseudorabies Virus Vaccine Sales 2019-2030
1.4.3 Global Pseudorabies Virus Vaccine Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Pseudorabies Virus Vaccine Market Competition by Manufacturers
2.1 Global Pseudorabies Virus Vaccine Sales Market Share by Manufacturers (2019-2024)
2.2 Global Pseudorabies Virus Vaccine Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Pseudorabies Virus Vaccine Average Price by Manufacturers (2019-2024)
2.4 Global Pseudorabies Virus Vaccine Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Pseudorabies Virus Vaccine, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Pseudorabies Virus Vaccine, Product Type & Application
2.7 Pseudorabies Virus Vaccine Market Competitive Situation and Trends
2.7.1 Pseudorabies Virus Vaccine Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Pseudorabies Virus Vaccine Players Market Share by Revenue
2.7.3 Global Pseudorabies Virus Vaccine Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Pseudorabies Virus Vaccine Retrospective Market Scenario by Region
3.1 Global Pseudorabies Virus Vaccine Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Pseudorabies Virus Vaccine Global Pseudorabies Virus Vaccine Sales by Region: 2019-2030
3.2.1 Global Pseudorabies Virus Vaccine Sales by Region: 2019-2024
3.2.2 Global Pseudorabies Virus Vaccine Sales by Region: 2025-2030
3.3 Global Pseudorabies Virus Vaccine Global Pseudorabies Virus Vaccine Revenue by Region: 2019-2030
3.3.1 Global Pseudorabies Virus Vaccine Revenue by Region: 2019-2024
3.3.2 Global Pseudorabies Virus Vaccine Revenue by Region: 2025-2030
3.4 North America Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.4.1 North America Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.4.3 North America Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.4.4 U.S.
3.4.5 Canada
3.5 Europe Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.5.1 Europe Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.5.3 Europe Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.6.1 Asia Pacific Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.6.3 Asia Pacific Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.6.13 Philippines
3.7 Latin America Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.7.1 Latin America Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.7.3 Latin America Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Pseudorabies Virus Vaccine Market Facts & Figures by Country
3.8.1 Middle East and Africa Pseudorabies Virus Vaccine Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Pseudorabies Virus Vaccine Sales by Country (2019-2030)
3.8.3 Middle East and Africa Pseudorabies Virus Vaccine Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 U.A.E
4 Segment by Type
4.1 Global Pseudorabies Virus Vaccine Sales by Type (2019-2030)
4.1.1 Global Pseudorabies Virus Vaccine Sales by Type (2019-2024)
4.1.2 Global Pseudorabies Virus Vaccine Sales by Type (2025-2030)
4.1.3 Global Pseudorabies Virus Vaccine Sales Market Share by Type (2019-2030)
4.2 Global Pseudorabies Virus Vaccine Revenue by Type (2019-2030)
4.2.1 Global Pseudorabies Virus Vaccine Revenue by Type (2019-2024)
4.2.2 Global Pseudorabies Virus Vaccine Revenue by Type (2025-2030)
4.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Type (2019-2030)
4.3 Global Pseudorabies Virus Vaccine Price by Type (2019-2030)
5 Segment by Application
5.1 Global Pseudorabies Virus Vaccine Sales by Application (2019-2030)
5.1.1 Global Pseudorabies Virus Vaccine Sales by Application (2019-2024)
5.1.2 Global Pseudorabies Virus Vaccine Sales by Application (2025-2030)
5.1.3 Global Pseudorabies Virus Vaccine Sales Market Share by Application (2019-2030)
5.2 Global Pseudorabies Virus Vaccine Revenue by Application (2019-2030)
5.2.1 Global Pseudorabies Virus Vaccine Revenue by Application (2019-2024)
5.2.2 Global Pseudorabies Virus Vaccine Revenue by Application (2025-2030)
5.2.3 Global Pseudorabies Virus Vaccine Revenue Market Share by Application (2019-2030)
5.3 Global Pseudorabies Virus Vaccine Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Merck
6.1.1 Merck Corporation Information
6.1.2 Merck Description and Business Overview
6.1.3 Merck Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Merck Pseudorabies Virus Vaccine Product Portfolio
6.1.5 Merck Recent Developments/Updates
6.2 Merial Limited
6.2.1 Merial Limited Corporation Information
6.2.2 Merial Limited Description and Business Overview
6.2.3 Merial Limited Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Merial Limited Pseudorabies Virus Vaccine Product Portfolio
6.2.5 Merial Limited Recent Developments/Updates
6.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd.
6.3.1 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Corporation Information
6.3.2 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Description and Business Overview
6.3.3 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.3.5 Boehringer Ingelheim Animal Health (USA) Co., Ltd. Recent Developments/Updates
6.4 Zoetis
6.4.1 Zoetis Corporation Information
6.4.2 Zoetis Description and Business Overview
6.4.3 Zoetis Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Zoetis Pseudorabies Virus Vaccine Product Portfolio
6.4.5 Zoetis Recent Developments/Updates
6.5 Hipra
6.5.1 Hipra Corporation Information
6.5.2 Hipra Description and Business Overview
6.5.3 Hipra Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.5.4 Hipra Pseudorabies Virus Vaccine Product Portfolio
6.5.5 Hipra Recent Developments/Updates
6.6 Anhui Divinity Biological Products
6.6.1 Anhui Divinity Biological Products Corporation Information
6.6.2 Anhui Divinity Biological Products Description and Business Overview
6.6.3 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.6.4 Anhui Divinity Biological Products Pseudorabies Virus Vaccine Product Portfolio
6.6.5 Anhui Divinity Biological Products Recent Developments/Updates
6.7 Wuhan Keqian Biological Co., Ltd.
6.6.1 Wuhan Keqian Biological Co., Ltd. Corporation Information
6.6.2 Wuhan Keqian Biological Co., Ltd. Description and Business Overview
6.6.3 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Wuhan Keqian Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.7.5 Wuhan Keqian Biological Co., Ltd. Recent Developments/Updates
6.8 China Biotechnology Co., Ltd.
6.8.1 China Biotechnology Co., Ltd. Corporation Information
6.8.2 China Biotechnology Co., Ltd. Description and Business Overview
6.8.3 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.8.4 China Biotechnology Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.8.5 China Biotechnology Co., Ltd. Recent Developments/Updates
6.9 CHINA ANIMAL HUSBANDRY INDUSTRY
6.9.1 CHINA ANIMAL HUSBANDRY INDUSTRY Corporation Information
6.9.2 CHINA ANIMAL HUSBANDRY INDUSTRY Description and Business Overview
6.9.3 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.9.4 CHINA ANIMAL HUSBANDRY INDUSTRY Pseudorabies Virus Vaccine Product Portfolio
6.9.5 CHINA ANIMAL HUSBANDRY INDUSTRY Recent Developments/Updates
6.10 Sichuan Huashen
6.10.1 Sichuan Huashen Corporation Information
6.10.2 Sichuan Huashen Description and Business Overview
6.10.3 Sichuan Huashen Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Sichuan Huashen Pseudorabies Virus Vaccine Product Portfolio
6.10.5 Sichuan Huashen Recent Developments/Updates
6.11 Haley
6.11.1 Haley Corporation Information
6.11.2 Haley Pseudorabies Virus Vaccine Description and Business Overview
6.11.3 Haley Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Haley Pseudorabies Virus Vaccine Product Portfolio
6.11.5 Haley Recent Developments/Updates
6.12 Tianbang
6.12.1 Tianbang Corporation Information
6.12.2 Tianbang Pseudorabies Virus Vaccine Description and Business Overview
6.12.3 Tianbang Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Tianbang Pseudorabies Virus Vaccine Product Portfolio
6.12.5 Tianbang Recent Developments/Updates
6.13 Dabei Nong
6.13.1 Dabei Nong Corporation Information
6.13.2 Dabei Nong Pseudorabies Virus Vaccine Description and Business Overview
6.13.3 Dabei Nong Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Dabei Nong Pseudorabies Virus Vaccine Product Portfolio
6.13.5 Dabei Nong Recent Developments/Updates
6.14 Harvey
6.14.1 Harvey Corporation Information
6.14.2 Harvey Pseudorabies Virus Vaccine Description and Business Overview
6.14.3 Harvey Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Harvey Pseudorabies Virus Vaccine Product Portfolio
6.14.5 Harvey Recent Developments/Updates
6.15 Preh Bio
6.15.1 Preh Bio Corporation Information
6.15.2 Preh Bio Pseudorabies Virus Vaccine Description and Business Overview
6.15.3 Preh Bio Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Preh Bio Pseudorabies Virus Vaccine Product Portfolio
6.15.5 Preh Bio Recent Developments/Updates
6.16 Jiangsu Nannong High-Tech Co.
6.16.1 Jiangsu Nannong High-Tech Co. Corporation Information
6.16.2 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Description and Business Overview
6.16.3 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Jiangsu Nannong High-Tech Co. Pseudorabies Virus Vaccine Product Portfolio
6.16.5 Jiangsu Nannong High-Tech Co. Recent Developments/Updates
6.17 Guangxi Liyuan Biological Co., Ltd.
6.17.1 Guangxi Liyuan Biological Co., Ltd. Corporation Information
6.17.2 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.17.3 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Guangxi Liyuan Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.17.5 Guangxi Liyuan Biological Co., Ltd. Recent Developments/Updates
6.18 Jilin Zhengye Bioengineering Group
6.18.1 Jilin Zhengye Bioengineering Group Corporation Information
6.18.2 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Description and Business Overview
6.18.3 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Jilin Zhengye Bioengineering Group Pseudorabies Virus Vaccine Product Portfolio
6.18.5 Jilin Zhengye Bioengineering Group Recent Developments/Updates
6.19 Jilin Heyuan Biological Engineering Co., Ltd.
6.19.1 Jilin Heyuan Biological Engineering Co., Ltd. Corporation Information
6.19.2 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.19.3 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.19.4 Jilin Heyuan Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.19.5 Jilin Heyuan Biological Engineering Co., Ltd. Recent Developments/Updates
6.20 Huapai Biological Engineering Group Co., Ltd.
6.20.1 Huapai Biological Engineering Group Co., Ltd. Corporation Information
6.20.2 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.20.3 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.20.4 Huapai Biological Engineering Group Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.20.5 Huapai Biological Engineering Group Co., Ltd. Recent Developments/Updates
6.21 Beijing Xinde Weite Technology Co., Ltd.
6.21.1 Beijing Xinde Weite Technology Co., Ltd. Corporation Information
6.21.2 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.21.3 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.21.4 Beijing Xinde Weite Technology Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.21.5 Beijing Xinde Weite Technology Co., Ltd. Recent Developments/Updates
6.22 Beijing Veterinary Biopharmaceutical Factory
6.22.1 Beijing Veterinary Biopharmaceutical Factory Corporation Information
6.22.2 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Description and Business Overview
6.22.3 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.22.4 Beijing Veterinary Biopharmaceutical Factory Pseudorabies Virus Vaccine Product Portfolio
6.22.5 Beijing Veterinary Biopharmaceutical Factory Recent Developments/Updates
6.23 Qilu Animal Health Products Co., Ltd.
6.23.1 Qilu Animal Health Products Co., Ltd. Corporation Information
6.23.2 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.23.3 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.23.4 Qilu Animal Health Products Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.23.5 Qilu Animal Health Products Co., Ltd. Recent Developments/Updates
6.24 Shanxi Longkel Bio-Pharmaceutical Co., Ltd.
6.24.1 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Corporation Information
6.24.2 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.24.3 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.24.4 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.24.5 Shanxi Longkel Bio-Pharmaceutical Co., Ltd. Recent Developments/Updates
6.25 Yunnan Biopharmaceutical Co.
6.25.1 Yunnan Biopharmaceutical Co. Corporation Information
6.25.2 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Description and Business Overview
6.25.3 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.25.4 Yunnan Biopharmaceutical Co. Pseudorabies Virus Vaccine Product Portfolio
6.25.5 Yunnan Biopharmaceutical Co. Recent Developments/Updates
6.26 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd.
6.26.1 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Corporation Information
6.26.2 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.26.3 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.26.4 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.26.5 Jiujiang Bomeilai Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
6.27 Liaoning Yikang Biological Co., Ltd.
6.27.1 Liaoning Yikang Biological Co., Ltd. Corporation Information
6.27.2 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.27.3 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.27.4 Liaoning Yikang Biological Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.27.5 Liaoning Yikang Biological Co., Ltd. Recent Developments/Updates
6.28 Shanghui Huahong Biological Engineering Co., Ltd.
6.28.1 Shanghui Huahong Biological Engineering Co., Ltd. Corporation Information
6.28.2 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.28.3 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.28.4 Shanghui Huahong Biological Engineering Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.28.5 Shanghui Huahong Biological Engineering Co., Ltd. Recent Developments/Updates
6.29 Sichuan Hailinge Biological Pharmaceutical Co., Ltd.
6.29.1 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Corporation Information
6.29.2 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.29.3 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.29.4 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.29.5 Sichuan Hailinge Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
6.30 Guangdong Yongshun Biological Pharmaceutical Co., Ltd.
6.30.1 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Corporation Information
6.30.2 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Description and Business Overview
6.30.3 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Sales, Revenue and Gross Margin (2019-2024)
6.30.4 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Pseudorabies Virus Vaccine Product Portfolio
6.30.5 Guangdong Yongshun Biological Pharmaceutical Co., Ltd. Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Pseudorabies Virus Vaccine Industry Chain Analysis
7.2 Pseudorabies Virus Vaccine Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Pseudorabies Virus Vaccine Production Mode & Process
7.4 Pseudorabies Virus Vaccine Sales and Marketing
7.4.1 Pseudorabies Virus Vaccine Sales Channels
7.4.2 Pseudorabies Virus Vaccine Distributors
7.5 Pseudorabies Virus Vaccine Customers
8 Pseudorabies Virus Vaccine Market Dynamics
8.1 Pseudorabies Virus Vaccine Industry Trends
8.2 Pseudorabies Virus Vaccine Market Drivers
8.3 Pseudorabies Virus Vaccine Market Challenges
8.4 Pseudorabies Virus Vaccine Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
